Sencar, Muhammed Erkam

Loading...
Profile Picture
Name Variants
Sencar, M. E.
M. E. Sencar
S., Muhammed Erkam
Sencar,M.E.
M., Sencar
Sancar, Muhammed Erkam
Sencar, M. Erkam
M.,Sencar
S.,Muhammed Erkam
Sencar, Erkam
Sencar M.
Muhammed Erkam, Sencar
Sencar, Muhammed Erkam
M.E.Sencar
Job Title
Doçent Doktor
Email Address
erkam.sencar@atilim.edu.tr
Main Affiliation
Internal Medical Sciences
Status
Website
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

SDG data is not available
This researcher does not have a Scopus ID.
Documents

65

Citations

424

Scholarly Output

2

Articles

2

Views / Downloads

2/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

0

Scopus Citation Count

0

Patents

0

Projects

0

WoS Citations per Publication

0.00

Scopus Citations per Publication

0.00

Open Access Source

1

Supervised Theses

0

JournalCount
European Archives of Oto-Rhino1
European Archives of Oto-Rhino-Laryngology1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Article
    Malignancy in Toxic Thyroid Adenoma: Revisiting Risk Assessment and Identifying Predictors
    (Springer, 2026) Calapkulu, Murat; Cayir, Derya; Sencar, Muhammed Erkam; Cakal, Erman; Sakiz, Davut; Unsal, Ilknur Ozturk; Tekinyildiz, Merve
    Background Toxic adenomas have traditionally been considered benign due to chronic TSH suppression, which is believed to inhibit thyroid tumorigenesis. However, emerging data challenge this dogma, reporting non-negligible malignancy rates even in toxic adenoma. This study aimed to assess thyroid cancer frequency and characteristics in surgically selected patients with toxic adenomas and to compare outcomes with propensity score-matched, surgically treated non-functioning nodules. Methods This retrospective, cross-sectional study included 204 surgically treated patients at a tertiary referral center, comprising 102 surgically selected toxic adenomas and 102 propensity score-matched, surgically treated non-functioning nodules. Clinical, biochemical, sonographic, scintigraphic, and histopathological data were analyzed. Multivariate logistic regression analysis was used to identify independent predictors of malignancy among toxic adenomas. Results In this surgically selected cohort, the malignancy rate was 16.7% for toxic adenomas and 40.2% for non-functioning nodules (p < 0.001). Papillary thyroid carcinoma comprised 82.4% of all cases, making it the leading histotype (82.4%). Among toxic nodules, higher fT4/fT3 ratio (cut-off:2.58, sensitivity:93.3%, specificity:54.2%) and European Thyroid Imaging and Reporting Data System categories 4-5 were independent predictors of malignancy. No significant differences were found between groups in terms of tumor size, invasion, American Thyroid Association risk stratification, or 5-year response rates. Conclusion Among surgically treated patients, the observed malignancy rate in toxic adenomas appears to be higher than traditionally expected. Elevated fT4/fT3 ratio and suspicious ultrasound features warrant closer evaluation. These findings support using ultrasound and biochemical markers in risk assessment of all thyroid nodules, regardless of functional status.